|Application:||Gene expression microarray analysis|
|Number of samples:||32|
|Release date:||Dec 9 2015|
|Last update date:||Jul 19 2017|
|Diseases:||Ataxia Telangiectasia, Deficiency Diseases, Lymphoma, Neoplasms, Leukemia, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse|
|Dataset link||ATM-deficient B cell lymphomas|
We performed gene expression profiling on nine ATMKO.CD3epsilonKO lymphoma cell lines (n=12, 3 technical repeats). We analyzed gene expression of anti-IgM stimulated primary B cells from both ATMKO.CD3epsilonKO (n=7, 5 technical repeats) and ATMWT.CD3epsilonKO mice (n=2), and GC B cells isolated from SRBC-immunized ATMWT mice (n=3, 1 biological repeat and 2 technical repeats). We analyzed gene expression following treatment of two ATMKO.CD3epsilonKO lymphoma cell lines with the BTK inhibitor, PCI-32765, at time points (1, 3, 6, and 24 hours) as compared to time points with vehicle (DMSO) (n=8).
Louis M. Staudt